The addition of belimumab to standard treatment in SLE patients was associated with decreased disease activity measured by SLEDAI score (up to 70%), lower absolute CD19 + B cell count and/or anti-DNA antibody levels, and clinical benefits improving overall symptoms. This evidence concerns the gene CD19 and systemic lupus erythematosus.